Synonym: BAY 86-9766, RDEA119
Refametinib (BAY 86-9766, RDEA119) is a potent, highly selective and ATP non-competitive inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively. Refametinib potently inhibited MEK activity as measured by phosphorylation of ERK1/2 across several human cancer cell lines of different tissue origins and BRAF mutational status with EC50 values ranging from 2.5 to 15.8 nM. RDEA119 inhibits anchorage-dependent growth of human cancer cell lines harboring the gain-of-function V600E BRAF mutant with GI50 values ranging from 67 to 89 nM. Refametinib (BAY 86-9766) exhibited potent antiproliferative activity in HCC cell lines with half-maximal inhibitory concentration values ranging from 33 to 762 nM. BAY 86-9766 was strongly synergistic with sorafenib in suppressing tumor cell proliferation and inhibiting phosphorylation of the extracellular signal-regulated kinase (ERK). Refametinib (BAY 869766, RDEA119) exhibits complete suppression of ERK phosphorylation at fully efficacious doses in mice. Refametinib (BAY 869766, RDEA119) shows a tissue selectivity that reduces its potential for central nervous system-related side effects.
|Cell lines||A375, SK-MEI-28, Colo205, HT-29 and BxPC3 cells|
|Preparation method||For anchorage-dependent growth inhibition experiments, plating cells in white 384-well plates at 1,000/20 μL/well or white 96-well microplates at 4,000/100 μL/well. After 24-h incubation at 37 °C, 5% CO2, and 100% humidity,incubating RDEA119 for 48 hours at 37 °C and assayed using CellTiter-Glo. For the 96-well anchorage-independent growth assay, filling wells of an “ultralow binding” plate (Corning) are with 60 μL of a 0.15% agarose solution in complete RPMI 1640. Then, adding 60 μL of complete RPMI 1640 which contains 9,000 cells in 0.15% agarose per well. 24 hourlater , adding 60 μL of a 3 × drug solution in agarose-free complete RPMI 1640 . 7 d later , 36 μL of 6 × 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)- 2H-tetrazolium, adding inner salt reagent per well. After 2 hours at 37 °C, determining absorbance at 490 nm on the M5 plate reader.|
|Incubation time||48 hours|
|Animal models||Female athymic nude mice are injected s.c. with A375, HT-29 and A431 tumor; male athymic nude mice with Colo205 tumor|
|Formulation||RDEA119 is dissolved in saline.|
|Dosages||25 or 50 mg/kg|
|Administration||Orally once daily for 14 days|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
Schmieder R, et al. Neoplasia. 2013 Oct;15(10):1161-71. PMID: 24204195.
BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.
Liu D, et al. Int J Cancer. 2010 Dec 15;127(12):2965-73. PMID: 21351275.
RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.
Iverson C, et al. Cancer Res. 2009 Sep 1;69(17):6839-47. PMID: 19706763.
|Related MEK Products|
BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively.
|AZD6244 sulfate salt|
LY2801653 is a potent, orally bioavailable, small-molecule inhibitor of c-MET kinase(Ki= 2 nM).
GDC-0973 is a potent, highly selective inhibitor of mitogen-activated protein kinase kinase (MEK1/2).
PD 198306 is a cell-permeable and highly selective MEK inhibitor with IC50 of 8 nM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.